BiotechTube

Nanatinostat in combination with valganciclovir

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epstein-Barr Virus Associated Lymphoma

Conditions

Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related PTLD, EBV-Related Lymphoproliferative Disorder

Trial Timeline

May 28, 2021 → Jan 31, 2025

NCT ID
NCT05011058

About Nanatinostat in combination with valganciclovir

Nanatinostat in combination with valganciclovir is a phase 2 stage product being developed by Viracta Therapeutics for Epstein-Barr Virus Associated Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05011058. Target conditions include Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05011058Phase 2Terminated

Competing Products

2 competing products in Epstein-Barr Virus Associated Lymphoma

See all competitors
ProductCompanyStageHype Score
Durvalumab + EpacadostatAstraZenecaPhase 2
52
tabelecleucelAtara BiotherapeuticsPre-clinical
15

Other Products from Viracta Therapeutics

Nanatinostat + Valganciclovir + PembrolizumabPhase 1
25
[14C]-Nanatinostat + Nanatinostat (free base) tablets in combination with Valganciclovir + Nanatinostat mesylate tablets in combination with Valganciclovir + Single-agent Nanatinostat (free base) tabletsPhase 1
25